Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

(2013) Cesarina Giallongo et al.   BMC CANCER

EZH2 in normal and malignant hematopoiesis

(2013) K Lund et al.   LEUKEMIA

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia

(2012) S. Tanaka et al.   BLOOD

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

(2012) P. Yan et al.   BLOOD

Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2

(2012) Ari Melnick   CANCER CELL

DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves as a Molecular Mark for Gene Silencing Memory

(2012) N. J.- M. Raynal et al.   CANCER RESEARCH

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia

(2012) Rainer Claus et al.   LEUKEMIA RESEARCH

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

(2010) Feng Xu et al.   ANNALS OF HEMATOLOGY

Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML

(2010) T. A. Paul et al.   BLOOD

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation

(2010) J. Si et al.   CANCER RESEARCH

Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer

(2010) Martin Sauvageau et al.   Cell Stem Cell

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

(2010) S Deneberg et al.   LEUKEMIA

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications

(2009) D. S. Schrump   CLINICAL CANCER RESEARCH

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

(2009) F. Sun et al.   MOLECULAR CANCER THERAPEUTICS

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer

(2008) Maryse Lemaire et al.   BMC CANCER

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE